Chartwell Investment Partners’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Chartwell Investment Partners’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-10,741	Closed	-$1.56M	–	439
2022 Q2	$1.56M	Buy	10,741 +268	+3%	+$34.2K	0.06%	306
2022 Q1	$1.24M	Buy	10,473 +359	+4%	+$44.8K	0.04%	360
2021 Q4	$1.39M	Buy	10,114 +2,303	+29%	+$293K	0.04%	354
2021 Q3	$1.08M	Sell	7,811 -41	-0.5%	-$5.12K	0.03%	371
2021 Q2	$762K	Buy	7,852 +19	+0.2%	+$1.54K	0.02%	392
2021 Q1	$535K	Sell	7,833 -230	-3%	-$18.6K	0.02%	394
2020 Q4	$691K	Buy	+8,063	New	+$683K	0.02%	386
2020 Q1	–	Sell	-20,342	Closed	-$1.11M	–	446
2019 Q4	$1.11M	Buy	+20,342	New	+$1.01M	0.04%	352
2017 Q4	–	Sell	-27,164	Closed	-$1.01M	–	440
2017 Q3	$1.01M	Buy	+27,164	New	+$824K	0.03%	381

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SFM

Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Chartwell Investment Partners's BHVN Position: Q3 2022 in Review

Chartwell Investment Partners sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 10,741 shares — an estimated $1.56M sold.

Chartwell Investment Partners first reported a position in BHVN in Q3 2017 and held it in 9 quarters. The position peaked at $1.56M in Q2 2022. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

Chartwell Investment Partners reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
Chartwell Investment Partners sold 10,741 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $1.56M.
Chartwell Investment Partners first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2017 and held it in 9 quarters.
Chartwell Investment Partners's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $1.56M in Q2 2022.
240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on Chartwell Investment Partners's 13F filing for Q3 2022, filed 27 Oct 2022.